Imagine if you could find out why you're in pain with a simple test instead of having surgery. This project creates a way to spot the genetic signatures of endometriosis without needing an operation. It also helps doctors pick the right existing medicine for a specific person's version of the disease, rather than using a one-size-fits-all approach.
Endometriosis takes an average of 8 years to diagnose, often requiring invasive surgery. This delay costs Europe €70bn per year and leaves 60% of cases undiagnosed.
A non-invasive precision medicine test to evaluate endometriosis risk and a system to match patients with repurposed drug candidates.
If you are a diagnostic company dealing with the high cost and risk of invasive surgical standards — this project developed a non-invasive precision medicine test that can be certified as a Class C IVDR device to capture a €4bn global market.
If you are a pharma company dealing with the high cost of new drug development — this project developed a mechanostic test that identifies which specific patient groups will benefit from repurposed drug candidates, speeding up the path to market.
If you are a clinic dealing with 8+ year diagnosis delays and long waiting lists — this project developed a rapid triage tool that reduces unnecessary surgeries and improves patient outcomes through earlier detection.
The project data does not specify the unit price of the test, but it describes the solution as an affordable and cost-effective alternative to expensive laparoscopy surgery.
Yes, the objective explicitly states the goal is to validate a scalable diagnostic solution to address a global market of 200 million affected women.
Based on available project data, the project focuses on certifying the diagnostic as a Class C IVDR device and identifying drug candidates for repurposing, though specific licensing terms are not listed.
The project must certify the novel diagnostic as a Class C IVDR device to ensure regulatory approval and market uptake.
The project runs from June 2025 to May 2027, with a commercial growth plan targeting specific revenue and staffing milestones by Year 5 post-project.
The consortium is highly industry-focused, consisting of 3 SMEs from the UK, Denmark, and Poland. With a 100% industry ratio and no university partners, the group is structured for rapid commercialization and regulatory approval rather than basic research.
Contact PrecisionLife Ltd in the UK
Contact us to explore licensing opportunities for the mechanostic platform.
